Navigation Links
Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1

-1, the most treatment-resistant type of HCV, and the majority of patients (74%) had high baseline viral load ( > 800,000 IU/ml), a well-established negative predictive factor for SVR. Patients received daily injections of omega interferon (25 mcg) for up to 48 weeks. The endpoints for this clinical trial were early viral response (EVR), defined as a 2-log reduction in HCV RNA after 12 weeks of treatment, and SVR, defined as undetectable HCV RNA 24 weeks after the end of 48 weeks of treatment. Response rates are presented in the table below:


         HCV RNA Results               Omega IFN + RBV   Omega IFN Alone


    (LOQ= 50 IU/ml)                          N=67              N=35


    Early Viral Response (EVR)               84%               60%

    p= 0.014


    Sustained Viral Response(SVR)            36%               6%

    p= 0.001


With this study, Intarcia also took a step toward testing its hypothesis that maintaining continuous drug levels through daily administration of omega interferon may minimize side effects when compared to current interferon therapies. This study to date has shown that omega interferon is well tolerated with only two discontinuations due to adverse events. Results of this Phase 2 study suggest a favorable overall safety profile with no substantial safety issues being identified. Normalization of serum ALT, a marker of reduced liver inflammation, occurred in 100% of patients achieving SVR and no patients receiving omega interferon with ribavirin experienced relapse during 24 weeks of follow-up after completing 48 weeks of treatment.

Alice Leung, President and Chief Executive Officer of Intarcia stated, "We are developing omega interferon to improve the treatment of HCV by offering a more convenient, potentially safer and more efficacious therapy. Based on the data so far, we believe that a continuous release formulation of omega interferon has the potential to become an important therapy for HCV pat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:12/24/2014)... , Dec. 23, 2014   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... (EMA) of the Marketing Authorization Application (MAA) for ... granted the company,s request for accelerated assessment, which ... review time.   The MAA, and ...
(Date:12/24/2014)... -- In response to urgent requests from the Deputy Minister of ... , Direct Relief delivered two 10-bed medical tents to ... local health workers who contract Ebola while fighting the outbreak. ... was constructed for foreign health care workers who may contract ... Sierra Leonean health workers. With Sierra ...
(Date:12/22/2014)... , Dec. 22, 2014 Apnea Sciences ( ... offices in Aliso Viejo , California.  ... to the tremendous growth and worldwide expansion, a new ... patented SnoreRx, the anti snore cure have exceeded our ... "We are now in 23 countries and will ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... INDIANAPOLIS, Jan. 18, 2011 Eli Lilly and Company (NYSE: ... the fourth quarter and full year of 2010 on Thursday, ... on that day with the investment community and media to ... conference call will be held from 9:00 a.m. to 10:00 ...
... Jan. 18, 2011 DW Healthcare Partners (DWHP), a ... announced the appointment of Bradley Lanham as the new ... DWHP has now completed acquisitions of institutional pharmacies specializing ... including Texas, Nevada, Utah, Idaho and Colorado. ...
Cached Medicine Technology:DW Healthcare Partners Announces New CEO on Heels of Increased Investment in Institutional Pharmacy Sector 2
(Date:12/25/2014)... 26, 2014 Recently, Dylan Queen, a ... excitedly released its collection of discounted prom dresses, most ... a senior spokesman of the company, the promotion is ... promotion is to expand the UK market. , The ... different colors, lengths, and styles: A-line strapless, empire strapless ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
(Date:12/25/2014)... Viejo, California (PRWEB) December 25, 2014 ... release of ProFire 5k. A fully customizable business presentation ... . , “Adding the ProFire 5k business tool, users ... Said Christina Austin, CEO of Pixel Film Studios. “ProFire ... look and style to add professionalism to a presentation” ...
(Date:12/24/2014)... Over 700 toys, that’s what AlignLife ... is 700 smiling little faces this holiday that might ... in monetary donations was given to the various charities ... they incur through the year. Some of the charities ... Haven , Shrine's Children's Hospitals, Toys for Tots and ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife Donates Over 700 Toys This Year 2
... - Estimated one-year, recurrence-free survival was 98% for Kit-positive ... placebo(1)- Historically, one in two patients experienced recurrence of ... - Gleevec is the only treatment in the US ... GIST after surgery; regulatory review is underway in the ...
... , Men with a limited life expectancy due to advanced age and existing medical conditions may not ... , Click here for more ... , , , ... , , ...
... Carry Extreme Physical Performance Products Including ANABEUTROL and ... March 18 Extreme Physical Performance is proud ... Nutrition Centers in an aggressive movement to increase ... ANABEUTROL(TM) and ANDRITEST(TM). GNC,s specialty retail locations number ...
... CHERRY HILL, N.J., March 18 Subaru of America, ... Edition to the Ronald McDonald House (RMH) of Southern ... Outback, valued at approximately $26,000, will be used to ... illnesses or traumatic injuries. The vehicle will also be ...
... EMERYVILLE, Calif., March 18 Bionovo, Inc. (Nasdaq: ... the unmet needs in women,s health and oncology, today announced ... presenting at the Wall Street Analyst Forum,s 20th Annual Institutional ... The event will be held at the University Club ...
... obesity, study found , , WEDNESDAY, March 18 (HealthDay News) -- ... whites, a long-running study shows. , "What we found is ... it is not a rare occurrence," said Dr. Kirsten Bibbins-Domingo, ... of the New England Journal of Medicine . "It ...
Cached Medicine News:Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 2Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 3Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 4Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 5Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 6Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 7Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 8Health News:Gleevec(R) substantially reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors (GIST), The Lancet reports 9Health News:US trial shows no early mortality benefit from annual prostate cancer screening 2Health News:US trial shows no early mortality benefit from annual prostate cancer screening 3Health News:US trial shows no early mortality benefit from annual prostate cancer screening 4Health News:US trial shows no early mortality benefit from annual prostate cancer screening 5Health News:US trial shows no early mortality benefit from annual prostate cancer screening 6Health News:Innovative Sports Supplement Firm Muscles Up to General Nutrition Centers in a New National Partnership 2Health News:Subaru of America Donates New Outback to Aid Ronald McDonald House Families 2Health News:Subaru of America Donates New Outback to Aid Ronald McDonald House Families 3Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 2Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 3Health News:Bionovo to Present at Wall Street Analyst Forum's 20th Annual Institutional Investor Conference 4Health News:High Rate of Early Heart Failure Seen in Blacks 2Health News:High Rate of Early Heart Failure Seen in Blacks 3
... This requiring no water ... long-lasting hand hygiene to physically ... washing is either not an ... Hibistat allows you to return ...
BETASEPT® Scrub 4% is for surgical handscrubbing, healthcare personnel hand-washing, preoperative patient prepping and general skin degerming....
... The Scrub Care® Brand soaps, emulsions, ... the ultimate in healthy skin care, ... keeping skin healthy and soft even ... do not contain petroleum-based substances that ...
... Scrub Care Scrub Brushes & ... choices to meet the demanding needs ... a preimpregnated scrub brush or prefer ... with bottled antimicrobial solution, scrub brushes ...
Medicine Products: